Join        Login             Stock Quote

Goldman Sachs Maintains Thoratec (THOR) As 'Neutral'

 April 05, 2012 12:50 PM

Goldman Sachs (GS) maintained its "Neutral" rating on shares of Thoratec Corp. (Nasdaq:THOR), a developer of ventricular assist devices used for circulatory support.

On Wednesday, the US Food & Drug Administration (FDA) announced it has classified the Thoratec HeartMate II left ventricular assist (LVAD) system recall as a Class I recall.

"While we think the recall has headline risk and may cause some concern in the clinical community near term, we see the issues at hand as addressable, and the company has identified a fix (new technique)," the brokerage wrote.

[Related -Gold hasn’t lost its allure in my portfolio]

Given that the heart failure patient population has no alternative therapy and that Thoratec has no immediate competition in the US, GS said it does not anticipate a material change to current 2012 Street forecasts.

GS estimates 2012 HeartMate II revenue in the US will be $220 million, or roughly 48% of total sales. Should problems persist, there could be a longer-term impact to Thoratec when new competition enters the market later this year, the brokerage said.

"Overall, we think THOR price action is more a response to headline risk than fundamental changes to the company, and see some near-term momentum in the shares," the brokerage wrote. "Still, competition in the US, a lack of major new products in 2012, and the need to invest in market development are keeping us on the sidelines."

[Related -Should You Buy HP's Stellar Rebound?]

On Thursday, the stock fell 0.15 percent to trade at $32.78. Over the past year, shares have been trading between $26.50 and $38.07.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageUS REITs Edged Higher Last Week As Emerging Markets Slumped

Real estate investment trusts (REITs) in the US took the lead in last week’s shortened holiday trading week read on...

article imageA Contrarian Perspective On The Short EuroTtrade

As the euro continues to drift lower, it has become the accepted wisdom that we are headed for parity with read on...

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Melt Up Or Melt Down?
More Articles on: Finance , Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.